CVM

CEL-SCI Corporation (CVM) - 10-Q Summary

Business Context and Reporting Period

Company: CEL-SCI Corporation (CEL-SCI)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Six months ended March 31, 2025 (Q2 Fiscal 2025)
Business Overview: CEL-SCI is a late clinical-stage biotechnology company focused on developing Multikine, an investigational immunotherapy for head and neck cancer, and L.E.A.P.S. technology for rheumatoid arthritis. The company has no approved products and generates no revenue.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses decreased slightly to $13.3 million from $13.6 million year-over-year. Research and Development (R&D) expenses declined by approximately 6% ($8.4M vs $9.0M), primarily due to a reduction in stock-based compensation expense. General and Administrative (G&A) expenses increased by 6% ($4.8M vs $4.6M), driven by higher public relations and accounting fees.
• Liquidity: Cash and cash equivalents decreased by approximately $2.8 million to $1.9 million. This decline was driven by $8.5 million in operating cash outflows and $1.0 million in finance lease payments, partially offset by $7.6 million in net proceeds from equity financings.
• Capital Structure: The company raised capital through the sale of common stock and pre-funded warrants in December 2024 and March 2025. Outstanding common shares increased from 63.8 million to 84.3 million during the period.
• Debt: Total liabilities decreased slightly. Finance lease liabilities remain significant, with a total obligation of approximately $10.4 million (undiscounted) and a net present value of $9.0 million.

Guidance, Outlook, and Risks

• Going Concern: The filing explicitly states there is substantial doubt about the company's ability to continue as a going concern due to recurring losses and future liquidity needs. The financial statements do not include adjustments that might result from this uncertainty.
• Capital Needs: The company estimates the cost of the required confirmatory registration study for Multikine to be approximately $30 million. Management plans to raise additional capital through corporate partnerships, debt, or equity financings to fund operations and the study.
• Regulatory Pathway: The FDA has indicated CEL-SCI may move forward with a 212-patient confirmatory registration study for Multikine in a specific target population (low PD-L1 expression, no lymph node involvement). The company aims to seek accelerated/conditional approval following full enrollment.
• Subsequent Event: On May 8, 2025, the company secured a $350,000 loan at 10% interest from an unaffiliated party, repayable from future partnering proceeds or financing.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2025, due to material weaknesses previously disclosed in the 10-K.

Investor Verification Checklist

• Cash Runway: Verify the current cash balance ($1.9M) against the estimated $30M cost for the confirmatory study and ongoing operating burn rate (~$8.5M per six months).
• Financing Terms: Review the terms of the December 2024 and March 2025 equity offerings, specifically the dilution impact of pre-funded warrants and the exercise prices.
• Lease Obligations: Assess the impact of the $9.0M finance lease liability (primarily for the San Tomas manufacturing facility) on future cash flow requirements.
• Regulatory Status: Confirm the current status of the FDA's agreement on the confirmatory study design and any new conditions imposed since the May 2024 announcement.
• Internal Controls: Monitor the company's remediation plan for the material weaknesses in internal controls over financial reporting.